{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T00:44:44Z","timestamp":1789865084516,"version":"4.0.1"},"reference-count":52,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chest"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.chest.2016.09.035","type":"journal-article","created":{"date-parts":[[2016,10,15]],"date-time":"2016-10-15T12:35:16Z","timestamp":1476534916000},"page":"78-89","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":90,"title":["Omalizumab Treatment Response in a Population With Severe Allergic Asthma and\u00a0Overlapping COPD"],"prefix":"10.1016","volume":"151","author":[{"given":"Steven","family":"Maltby","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter G.","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Powell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa M.","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.chest.2016.09.035_bib1","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1183\/13993003.00853-2015","article-title":"A\u00a0summary of the new GINA strategy:a roadmap to asthma control","volume":"46","author":"Reddel","year":"2015","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.chest.2016.09.035_bib2","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1164\/rccm.201204-0596PP","article-title":"Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary","volume":"187","author":"Vestbo","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.chest.2016.09.035_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40266-012-0042-z","article-title":"Managing older patients with coexistent asthma and chronic obstructive pulmonary disease: diagnostic and therapeutic challenges","volume":"30","author":"McDonald","year":"2013","journal-title":"Drugs Aging"},{"issue":"7","key":"10.1016\/j.chest.2016.09.035_bib4","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1136\/thoraxjnl-2014-206740","article-title":"Asthma-COPD overlap 2015: now we are six","volume":"70","author":"Gibson","year":"2015","journal-title":"Thorax"},{"issue":"7","key":"10.1016\/j.chest.2016.09.035_bib5","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.rmed.2013.03.007","article-title":"Characterisation of the overlap COPD-asthma phenotype. Focus on physical activity and health status","volume":"107","author":"Miravitlles","year":"2013","journal-title":"Respir Med"},{"issue":"2","key":"10.1016\/j.chest.2016.09.035_bib6","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1183\/09031936.00216013","article-title":"The clinical and genetic features of COPD-asthma overlap syndrome","volume":"44","author":"Hardin","year":"2014","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.chest.2016.09.035_bib7","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1378\/chest.13-0622","article-title":"Increased risk of exacerbation and hospitalization in subjects with an overlap phenotype: COPD-asthma","volume":"145","author":"Menezes","year":"2014","journal-title":"Chest"},{"key":"10.1016\/j.chest.2016.09.035_bib8","unstructured":"Global Initiative for Asthma\/Global Initiative for Chronic Obstructive Lung Disease. Diagnosis of Diseases of Chronic Airflow Limitation: Asthma COPD and Asthma-COPD Overlap Syndrome (ACOS),\u00a02015."},{"issue":"2","key":"10.1016\/j.chest.2016.09.035_bib9","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1183\/13993003.01359-2015","article-title":"Treatable traits: toward precision medicine of chronic airway diseases","volume":"47","author":"Agusti","year":"2016","journal-title":"Eur\u00a0Respir J"},{"issue":"7","key":"10.1016\/j.chest.2016.09.035_bib10","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1586\/17512433.2016.1172208","article-title":"Targeted therapeutics for severe refractory asthma:monoclonal antibodies","volume":"9","author":"Grainge","year":"2016","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.chest.2016.09.035_bib11","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1164\/rccm.201211-2103OC","article-title":"Effects of allergic phenotype on respiratory symptoms and exacerbations in patients with chronic obstructive pulmonary disease","volume":"188","author":"Jamieson","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.chest.2016.09.035_bib12","first-page":"296","article-title":"Evaluation of atopy in patients with COPD","volume":"39","author":"Neves","year":"2013","journal-title":"J\u00a0Bras Pneumol"},{"issue":"10","key":"10.1016\/j.chest.2016.09.035_bib13","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1046\/j.1365-2222.1998.00382.x","article-title":"The\u00a0importance of serum IgE for level and\u00a0longitudinal change in airways hyperresponsiveness in COPD","volume":"28","author":"Renkema","year":"1998","journal-title":"Clin Exp Allergy"},{"issue":"6","key":"10.1016\/j.chest.2016.09.035_bib14","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.rmed.2006.10.011","article-title":"External validity of randomized controlled trials in COPD","volume":"101","author":"Travers","year":"2007","journal-title":"Respir Med"},{"issue":"3","key":"10.1016\/j.chest.2016.09.035_bib15","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1136\/thx.2006.066837","article-title":"External validity of randomised controlled trials in asthma: to whom do the results of\u00a0the trials apply?","volume":"62","author":"Travers","year":"2007","journal-title":"Thorax"},{"issue":"2","key":"10.1016\/j.chest.2016.09.035_bib16","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3109\/02770903.2011.648296","article-title":"A\u00a026-week, randomized, double-blind, placebo-controlled, multicenter study to evaluate the effect of omalizumab on asthma control in patients with persistent allergic asthma","volume":"49","author":"Bardelas","year":"2012","journal-title":"J\u00a0Asthma"},{"issue":"11","key":"10.1016\/j.chest.2016.09.035_bib17","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/j.rmed.2010.07.011","article-title":"Omalizumab-induced decrease of FcxiRI expression in patients with severe allergic asthma","volume":"104","author":"Chanez","year":"2010","journal-title":"Respir Med"},{"issue":"2","key":"10.1016\/j.chest.2016.09.035_bib18","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1067\/mai.2001.117880","article-title":"Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the\u00a0treatment of severe allergic asthma","volume":"108","author":"Busse","year":"2001","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"9","key":"10.1016\/j.chest.2016.09.035_bib19","doi-asserted-by":"crossref","first-page":"573","DOI":"10.7326\/0003-4819-154-9-201105030-00002","article-title":"Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial","volume":"154","author":"Hanania","year":"2011","journal-title":"Ann Intern Med"},{"issue":"11","key":"10.1016\/j.chest.2016.09.035_bib20","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa1009705","article-title":"Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children","volume":"364","author":"Busse","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.chest.2016.09.035_bib21","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jaci.2012.07.047","article-title":"Omalizumab is effective in allergic and nonallergic patients with nasal polyps and\u00a0asthma","volume":"131","author":"Gevaert","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.chest.2016.09.035_bib22","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1365-2222.2004.1916.x","article-title":"Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma","volume":"34","author":"Holgate","year":"2004","journal-title":"Clin Exp Allergy"},{"issue":"8","key":"10.1016\/j.chest.2016.09.035_bib23","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1111\/j.1440-1843.2009.01633.x","article-title":"Efficacy and safety of omalizumab in an Asian population with moderate-to-severe persistent asthma","volume":"14","author":"Ohta","year":"2009","journal-title":"Respirology"},{"issue":"2","key":"10.1016\/j.chest.2016.09.035_bib24","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1183\/09031936.01.00092101","article-title":"The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics","volume":"18","author":"Soler","year":"2001","journal-title":"Eur Respir J"},{"issue":"7","key":"10.1016\/j.chest.2016.09.035_bib25","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1398-9995.2004.00550.x","article-title":"Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR","volume":"59","author":"Vignola","year":"2004","journal-title":"Allergy"},{"issue":"2","key":"10.1016\/j.chest.2016.09.035_bib26","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.rmed.2009.09.011","article-title":"Effect of\u00a0omalizumab on peripheral blood eosinophilia in allergic asthma","volume":"104","author":"Massanari","year":"2010","journal-title":"Respir Med"},{"issue":"3","key":"10.1016\/j.chest.2016.09.035_bib27","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1398-9995.2004.00772.x","article-title":"Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment):INNOVATE","volume":"60","author":"Humbert","year":"2005","journal-title":"Allergy"},{"issue":"26","key":"10.1016\/j.chest.2016.09.035_bib28","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1056\/NEJM199912233412603","article-title":"Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group","volume":"341","author":"Milgrom","year":"1999","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.chest.2016.09.035_bib29","doi-asserted-by":"crossref","first-page":"E36","DOI":"10.1542\/peds.108.2.e36","article-title":"Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab)","volume":"108","author":"Milgrom","year":"2001","journal-title":"Pediatrics"},{"issue":"6","key":"10.1016\/j.chest.2016.09.035_bib30","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/j.jaci.2009.09.021","article-title":"Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma","volume":"124","author":"Lanier","year":"2009","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"suppl 3","key":"10.1016\/j.chest.2016.09.035_bib31","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1111\/j.1440-1843.2007.01047.x","article-title":"Use of omalizumab in a severe asthma clinic","volume":"12","author":"Gibson","year":"2007","journal-title":"Respirology"},{"issue":"5","key":"10.1016\/j.chest.2016.09.035_bib32","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/all.12815","article-title":"\u201cReal-life\u201d effectiveness studies of omalizumab in adult patients with severe allergic asthma: systematic review","volume":"71","author":"Abraham","year":"2016","journal-title":"Allergy"},{"key":"10.1016\/j.chest.2016.09.035_bib33","first-page":"1CD003559","article-title":"Omalizumab for asthma in adults and children","author":"Normansell","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"10.1016\/j.chest.2016.09.035_bib34","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1164\/rccm.200312-1651OC","article-title":"Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma","volume":"170","author":"Djukanovic","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.chest.2016.09.035_bib35","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1159\/000250436","article-title":"Reduced FcepsilonRI-mediated release of\u00a0asthma-promoting cytokines and chemokines from human basophils during omalizumab therapy","volume":"151","author":"Oliver","year":"2010","journal-title":"Int Arch Allergy Immunol"},{"issue":"4","key":"10.1016\/j.chest.2016.09.035_bib36","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jaci.2009.10.021","article-title":"Decreases in human dendritic cell-dependent T(H)2-like responses after acute in\u00a0vivo IgE neutralization","volume":"125","author":"Schroeder","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.chest.2016.09.035_bib37","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/2045-7022-3-29","article-title":"Omalizumab may decrease IgE synthesis by targeting membrane IgE+ human B cells","volume":"3","author":"Chan","year":"2013","journal-title":"Clin Transl Allergy"},{"issue":"9","key":"10.1016\/j.chest.2016.09.035_bib38","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1111\/imj.13166","article-title":"Effectiveness and response predictors of omalizumab in a severe allergic asthma population with a high prevalence of comorbidities: the Australian Xolair Registry","volume":"46","author":"Gibson","year":"2016","journal-title":"Intern Med J"},{"key":"10.1016\/j.chest.2016.09.035_bib39","doi-asserted-by":"crossref","unstructured":"Hew M, Gillman A, Sutherland M, et\u00a0al. Real-life effectiveness of omalizumab in\u00a0severe allergic asthma above the recommended dosing range criteria [published online ahead of print July 5, 2016]. Clin Exp Allergy. http:\/\/dx.doi.org\/10.1111\/cea.12774.","DOI":"10.1111\/cea.12774"},{"issue":"5","key":"10.1016\/j.chest.2016.09.035_bib40","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.rmed.2004.10.008","article-title":"Measurement properties and interpretation of three shortened versions of the asthma control questionnaire","volume":"99","author":"Juniper","year":"2005","journal-title":"Respir Med"},{"issue":"5","key":"10.1016\/j.chest.2016.09.035_bib41","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1378\/chest.115.5.1265","article-title":"Validation of a standardized version of the Asthma Quality of Life\u00a0Questionnaire","volume":"115","author":"Juniper","year":"1999","journal-title":"Chest"},{"issue":"9","key":"10.1016\/j.chest.2016.09.035_bib42","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1136\/thx.2010.137414","article-title":"Refractory asthma in the UK: cross-sectional findings from a UK multicentre registry","volume":"65","author":"Heaney","year":"2010","journal-title":"Thorax"},{"issue":"2","key":"10.1016\/j.chest.2016.09.035_bib43","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaci.2006.11.639","article-title":"Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program","volume":"119","author":"Moore","year":"2007","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.chest.2016.09.035_bib44","doi-asserted-by":"crossref","first-page":"253","DOI":"10.3109\/08923973.2016.1173057","article-title":"Omalizumab (anti-IgE) therapy in the asthma-COPD overlap syndrome (ACOS) and its effects on circulating cytokine levels","volume":"38","author":"Yalcin","year":"2016","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"10.1016\/j.chest.2016.09.035_bib45","first-page":"1","article-title":"Omalizumab treatment in asthma-COPD overlap syndrome","author":"Tat","year":"2016","journal-title":"J\u00a0Asthma"},{"issue":"11","key":"10.1016\/j.chest.2016.09.035_bib46","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/j.rmed.2009.05.002","article-title":"Omalizumab in patients with severe persistent allergic asthma in a real-life setting in Germany","volume":"103","author":"Korn","year":"2009","journal-title":"Respir Med"},{"issue":"11","key":"10.1016\/j.chest.2016.09.035_bib47","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/S2213-2600(14)70187-0","article-title":"Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study","volume":"2","author":"Brightling","year":"2014","journal-title":"Lancet Respir Med"},{"issue":"5","key":"10.1016\/j.chest.2016.09.035_bib48","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1183\/09031936.99.14510099","article-title":"Bronchodilator responsiveness and serum total IgE levels in families of probands with severe early-onset COPD","volume":"14","author":"Celedon","year":"1999","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.chest.2016.09.035_bib49","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0954-6111(97)90070-6","article-title":"Peripheral blood\u00a0lymphocyte cell subsets in subjects with chronic obstructive pulmonary disease: association with smoking, IgE and lung function","volume":"91","author":"de Jong","year":"1997","journal-title":"Respir Med"},{"key":"10.1016\/j.chest.2016.09.035_bib50","first-page":"15130","article-title":"The prevalence of increased serum IgE and Aspergillus sensitization in patients with COPD and their association with symptoms and\u00a0lung function","author":"Jin","year":"2014","journal-title":"Respir Res"},{"key":"10.1016\/j.chest.2016.09.035_bib51","first-page":"6181","article-title":"Lower FEV1 in non-COPD, nonasthmatic subjects: association with smoking, annual decline in FEV1, total IgE levels, and TSLP genotypes","author":"Masuko","year":"2011","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"1","key":"10.1016\/j.chest.2016.09.035_bib52","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1164\/ajrccm.152.1.7599870","article-title":"Longitudinal evaluation of the association between pulmonary function and total serum IgE","volume":"152","author":"Sherrill","year":"1995","journal-title":"Am J Respir Crit Care Med"}],"updated-by":[{"DOI":"10.1016\/j.chest.2017.01.016","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000}}],"container-title":["Chest"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369216607547?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369216607547?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,7]],"date-time":"2018-09-07T12:52:22Z","timestamp":1536324742000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369216607547"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S0012369216607547"],"URL":"https:\/\/doi.org\/10.1016\/j.chest.2016.09.035","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.chest.2017.01.016","asserted-by":"object"}]},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Omalizumab Treatment Response in a Population With Severe Allergic Asthma and\u00a0Overlapping COPD","name":"articletitle","label":"Article Title"},{"value":"Chest","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chest.2016.09.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}